The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESTRO 2026 | Follow-up to the MODERN-LUNG trial of hypofractionated radiotherapy in lung cancer
Shalini Vinod, MBBS, MD, University of New South Wales, Liverpool, Australia, discusses a follow-up Phase III randomized trial to the MODERN-LUNG trial (ACTRN12620001198910), which will evaluate the MODERN-LUNG regimen of 55GY in 20 fractions against 60-66Gy in 30-33 fractions in unresectable stage III non-small cell lung cancer (NSCLC). Patient input has been considered to design a combined primary endpoint of progression-free survival, treatment burden for patients, quality of life and toxicity. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
